Phase 3 program to evaluate the Safety and Efficacy of Upadacitinib in subjects with moderate to severely active Systemic Lupus Erythematosus (SLE).

Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems. This study will assess how safe and effective upadacitinib is in treating adult participants with moderately to severely active SLE. Adverse events and change in the disease activity will be assessed.

For more information please visit https://clinicaltrials.gov/study/NCT05843643

Interested in Volunteering for the Study?

If you would like more information about this study, please call us at 318-212-8130 .